Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue

Basic and Clinical Pharmacology and Toxicology

Volumn 100, Issue 1, 2007, Pages 49-58

  Ferdinandi, Eckhardt S ^a,e   Brazeau, Paul ^b   High, Kim ^a   Procter, Bryan ^c   Fennell, Stephen ^a   Dubreuil, Pascal ^d  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^b NOTRE DAME HOSPITAL   (Canada)

^c ITR Laboratories Canada Inc   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e Theratechnologies Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR AMIDE; GROWTH HORMONE RELEASING FACTOR DERIVATIVE; SOMATOMEDIN; TH 9507; UNCLASSIFIED DRUG;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; CLINICAL CHEMISTRY; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG DEGRADATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG ELIMINATION; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; GROWTH HORMONE BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; IN VITRO STUDY; KIDNEY; LIVER; MALE; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; RAT; SWINE; TOXICITY TESTING; TREATMENT DURATION;

ANIMALS; BODY WEIGHT; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; GROWTH HORMONE; GROWTH HORMONE-RELEASING HORMONE; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INSULIN-LIKE GROWTH FACTOR I; LIPODYSTROPHY; MALE; ORGAN SIZE; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; SPECIFIC PATHOGEN-FREE ORGANISMS; SWINE; TOXICITY TESTS;

CANIS FAMILIARIS;

EID: 33846009834     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2007.00008.x     Document Type: Article

References (35)

1. Frohman LA, Kineman RD. Growth hormone-releasing hormone: discovery, regulation, and actions. In: Kostyo J (ed.). Handbook of Physiology: Hormonal Control of Growth. Oxford University Press, New York, 1999;189-221.
2. Guillemin R, Brazeau P, Bohlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science 1982;218:585-7.
3. Rivier J, Spiess J, Thorner M, Vale W. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature 1982;300:276-8.
4. Bohlen P, Brazeau P, Bloch B, Ling N, Gaillard R, Guillemin R. Human hypothalamic growth hormone-releasing factor (GRF): evidence for two forms identical to tumor derived GRF-44-NH2 and GRF-40. Biochem Biophys Res Commun 1983;114:930-6.
5. Ling N, Esch F, Bohlen P, Brazeau P, Wehrenberg WP, Guillemin R. Isolation, primary structure, and synthesis of human hypothalamic somatocrinin: growth hormone-releasing factor. Proc Natl Acad Sci USA 1984;81:4302-6.
6. Esch FS, Bohlen P, Ling N, Brazeau P, Guillemin R. Isolation and characterization of the bovine hypothalamic growth hormone-releasing factor. Biochem Biophys Res Commun 1983;117:772-9.
7. Bohlen P, Esch F, Brazeau B, Ling N, Guillemin R. Isolation and characterization of the porcine hypothalamic growth hormone releasing factor. Biochem Biophys Res Commun 1983;116:726-34.
8. Bohlen P, Wehrenberg WP, Esch F, Ling N, Brazeau P, Guillemin R. Rat hypothalamic growth hormone-releasing factor: isolation, sequence analysis and total synthesis. Biochem Biohys Res Commun 1984;125:1005-12.
9. Brazeau P, Bohlen P, Esch F, Ling N, Wehrenberg WB, Guillemin R. Growth hormone-releasing factor from ovine and caprine hypothalamus: isolation, sequence analysis and total synthesis. Biochem Biophys Res Commun 1984;125:606-14.
10. Fisher LB, Cachet NM, Barzu-Le-Roux S. Canine GHRH gene, polypeptides and methods of use. International Patent WO 2004/108761 A2.
11. Campbell RM, Bongers J, Felix AM. Rational design, synthesis, and biological evaluation of novel growth hormone-releasing factor analogues. Biopolymers 1995;37:67-88.
12. Brazeau P, Bohlen P, Esch F et al. Growth hormone-releasing factor: isolation, characterization, and physiology. In: Raiti S, Tolman RA (eds). Human Growth Hormone. Plenum Publishing Corp., New York. 1996;337-46.
13. Frohman LA, Downs TR, Williams TC, Heimer EP, Pan YC, Felix AM. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. J Clin Invest 1986;78:906-13.
14. Kubiak TM, Kelly CR, Krabill LF. In vitro metabolic degradation of a bovine growth hormone-releasing factor analog Leu27-bGRF(1-29)NH2 in bovine and porcine plasma. Correlation with plasma dipeptidylpeptidase activity. Drug Metab Dispos 1989;17:393-7.
15. Ling N, Baird A, Wehrenberg WB et al. Synthesis and in vitro bioactivity of human growth hormone-releasing factor analogs substituted at position-1. Biochem Biophys Res Commun 1984;122:304-10.
16. Dubreuil P, Désévaux C. Growth hormone-releasing factor: structural modification and protection for more potent analogues. Comb Chem High Throughput Screen 2006;9:171-4.
17. Ford JJ, Maurer RR. Simple technique for chronic venous catheterization of swine. Lab Anim Sci 1978;28:615-8.
18. Abribat T, Regnier A, Morre M. Growth hormone response induced by synthetic human growth hormone-releasing factor (1-44) in healthy dogs. Zentralbl Veterinarmed A 1989;36:367-73.
19. Jansen M, Darby I, Abribat T, Dubreuil P, Ferdinandi ES, Hardy JG. Pulmonary delivery of TH9507, a growth hormone-releasing factor analogue, in the dog. Int J Pharm 2004;276:75-81.
20. Dubreuil P, Petitclerc D, Pelletier G et al. Effect of dose and frequency of administration of a potent analog of human growth hormone-releasing factor on hormone secretion and growth in pigs. J Anim Sci 1990;68:1254-68.
21. Dubreuil P, Petitclerc D, Gaudreau P, Brazeau P, Pelletier G. Effect of growth hormone-releasing factor infusion on somatotropin, prolactin, thyroxine, insulin, insulin-like growth factor I and blood metabolites in control and somatostatin-immunized growing pigs. Domest Anim Endocrinol 1991;8:307- 21.
22. Dhir RN, Shapiro BH. Interpulse growth hormone secretion in the episodic plasma profile causes the sex reversal of cytochrome P450s in senescent male rats. Proc Natl Acad Sci USA 2003;100:15224-8.
23. Frohman LA, Downs TR, Heimer EP, Felix AM. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J Clin Invest 1989;1533-40.
24. Campbell RM, Lee Y, Rivier J, Heimer EP, Felix AM, Mowles TF. GRF analogs and fragments: correlation between receptor binding, activity and structure. Peptides 1991;12:569-74.
25. Dubreuil P, Brazeau P, Moreau S, Farmer C, Coy D, Abribat T. The use of pigs as an animal model to evaluate the efficacy, potency and specificity of two growth hormone releasing factor analogues. Growth Horm IGF Res 2001;11:173-86.
26. Jorgensen KD, Svendsen O, Greenough RJ et al. Biosynthetic human growth hormone: subchronic toxicity studies in rats and monkeys. Pharmacol Toxicol 1988;62:329-33.
27. Prahalada S, Stabinski LG, Chen HY et al. Pharmacological and toxicological effects of chronic porcine growth hormone administration in dogs. Toxicol Pathol 1998;26:185-200.
28. McCusker RH. Controlling insulin-like growth factor activity and the modulation of insulin-like growth factor binding protein and receptor binding. J Dairy Sci 1998;81:1790-800.
29. Johansson AG, Engstrom BE, Ljunghall S, Karlsson FA, Burman P. Gender differences in the effects of long term growth hormone (GH) treatment on bone in adults with GH deficiency. J Clin Endocrinol Metab 1999;84:2002-7.
30. Eden-Engstom B, Burman P, Johansson AG, Wide L, Karlsson FA. Effects of short-term administration of growth hormone in healthy young men, women, and women taking oral contraceptives. J Intern Med 2000;247:570-8.
31. Butler AA, Yakar S, LeRoith D. Insulin-like growth factor-I: compartmentalization within the somatotropic axis? News Physiol Sci 2002;17:82-5.
32. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3-34.
33. Bick T, Hochberg Z, Amit T, Isaksson OG, Jansson JO. Roles of pulsatility and continuity of growth hormone (GH) administration in the regulation of hepatic GH-receptors, and circulating GH-binding protein and insulin-like growth factor-I. Endocrinology 1992;131:423-9.
34. Laroque P, Molon-Noblot S, Prahalada S et al. Morphological changes in the pituitary gland of dogs chronically exposed to exogenous growth hormone. Toxicol Pathol 1998;26:201-6.
35. Falutz J, Allas S, Kotler D et al. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS 2005;19:1279-87.